4//SEC Filing
GOODMAN COREY S 4
Accession 0001567619-22-010353
CIK 0001651431other
Filed
May 11, 8:00 PM ET
Accepted
May 12, 8:47 PM ET
Size
16.5 KB
Accession
0001567619-22-010353
Insider Transaction Report
Form 4
venBio Global Strategic Fund II L.P.
10% Owner
Transactions
- Sale
Common Stock
2022-05-10$10.38/sh−18,676$193,870→ 2,429,805 total - Sale
Common Stock
2022-05-11$10.38/sh−17,700$183,641→ 2,412,105 total - Sale
Common Stock
2022-05-12$10.39/sh−124,525$1,294,313→ 2,287,580 total
venBio Global Strategic GP II, L.P.
10% Owner
Transactions
- Sale
Common Stock
2022-05-12$10.39/sh−124,525$1,294,313→ 2,287,580 total - Sale
Common Stock
2022-05-10$10.38/sh−18,676$193,870→ 2,429,805 total - Sale
Common Stock
2022-05-11$10.38/sh−17,700$183,641→ 2,412,105 total
venBio Global Strategic GP II, Ltd.
10% Owner
Transactions
- Sale
Common Stock
2022-05-12$10.39/sh−124,525$1,294,313→ 2,287,580 total - Sale
Common Stock
2022-05-11$10.38/sh−17,700$183,641→ 2,412,105 total - Sale
Common Stock
2022-05-10$10.38/sh−18,676$193,870→ 2,429,805 total
Adelman Robert J
10% Owner
Transactions
- Sale
Common Stock
2022-05-10$10.38/sh−18,676$193,870→ 2,429,805 total - Sale
Common Stock
2022-05-11$10.38/sh−17,700$183,641→ 2,412,105 total - Sale
Common Stock
2022-05-12$10.39/sh−124,525$1,294,313→ 2,287,580 total
GOODMAN COREY S
10% Owner
Transactions
- Sale
Common Stock
2022-05-10$10.38/sh−18,676$193,870→ 2,429,805 total - Sale
Common Stock
2022-05-11$10.38/sh−17,700$183,641→ 2,412,105 total - Sale
Common Stock
2022-05-12$10.39/sh−124,525$1,294,313→ 2,287,580 total
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.435, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
Documents
Issuer
Checkmate Pharmaceuticals, Inc.
CIK 0001651431
Entity typeother
Related Parties
1- filerCIK 0001278411
Filing Metadata
- Form type
- 4
- Filed
- May 11, 8:00 PM ET
- Accepted
- May 12, 8:47 PM ET
- Size
- 16.5 KB